View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.

       

News

Regeneus Ltd (ASX:RGS) Chairman's Address to Shareholders and CEO AGM Presentation

🕔11/21/2019 3:15:30 PM 1053

2019 was a productive year as we continued our aim of commercialising Progenza and Sygenus, our core regenerative medicine technology platforms. In particular, our focus has been on the lead platform, Progenza, which has shown positive results for treating osteoarthritis in its Phase 1 trials.

Read Full Article

Regeneus Ltd (ASX:RGS) Japanese Biotech Fund takes up all Rights Issue Shortfall

🕔11/19/2019 10:40:44 AM 1109

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, has placed the full shortfall of 9,437,872 shares under its recent Non-Renounceable Rights Issue. The shortfall was placed to a Japan-based institutional investor at an issue price of A$0.08 per share for a total of A$755,029.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔10/31/2019 1:38:20 PM 933

Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today released its quarterly cashflow report for the period ending 30 September 2019 (Q1 FY20).

Read Full Article

Regeneus Ltd (ASX:RGS) Annual Report 2019

🕔10/30/2019 8:15:27 AM 1024

Regeneus Ltd (ASX:RGS) is a Sydney Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell cell-based therapies to address significant unmet medical needs in the human health markets.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives A$1.5 million in R&D Tax Incentives

🕔10/15/2019 11:08:59 AM 1165

Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, has received $1.5 million in R&D Tax Incentives from the Australian Tax Office for FY19.

Read Full Article

Regeneus Ltd (ASX:RGS) Financial Report - Year Ended 30 June 2019

🕔9/26/2019 9:32:37 AM 1676

Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, releases its financial results for the financial year ended 30 June 2019 (FY2019).

Read Full Article

Regeneus Ltd (ASX:RGS) Appoints International Directors for Global Growth

🕔4/29/2019 8:48:54 AM 2444

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the appointment of John Chiplin, PhD and Alan W. Dunton, M.D. to its Board of Directors, effective 29 April 2019 as independent, Non-Executive Directors.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Results

🕔4/11/2019 10:48:52 AM 2596

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 March, 2019.

Read Full Article

Regeneus Ltd (ASX:RGS) Half-Year Report

🕔3/1/2019 8:08:49 AM 3142

Regeneus (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company developing a portfolio of novel cell-based therapies targeting significant unmet medical needs in human and animal health, with an initial focus on osteoarthritis, neuropathic pain and dermatology. The Company's product pipeline is underpinned by proprietary stem cell technologies.

Read Full Article

Regeneus Ltd (ASX:RGS) Directors Provide $2.5M Loan to Extend Funding Runway

🕔2/28/2019 1:27:23 PM 3089

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that its Board of Directors have put in place loan funding of $2.5m to extend the Company's funding runway for the development and licensing of its clinical assets.

Read Full Article
###

126,498 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 232) (Last 30 Days: 1349) (Since Published: 58423) 

Company Data

    Headquarters
  • 2 Paddington Street
    Paddington NSW 2021
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports